NRG-GI004 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Details
Age
Adult
Type of Study
Treatment
Locations
Cherry Creek Medical Center
Greeley Campus
Harmony Campus
Highlands Ranch Hospital
Medical Center of the Rockies
Memorial Hospital Central
Memorial Hospital North
Poudre Valley Hospital
University of Colorado Hospital
Principal Investigator

Alexis Leal, MD
Study ID
Protocol Number: 18-0018
More information available at ClinicalTrials.gov: NCT02997228
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers